TuisPRE • NASDAQ
add
Prenetics Global Ltd
Vorige sluiting
$4,61
Dagwisseling
$4,42 - $4,42
Jaarwisseling
$2,85 - $7,84
Markkapitalisasie
54,00 m USD
Gemiddelde volume
11,72 k
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(USD) | Jun. 2024info | J/J-verandering |
---|---|---|
Inkomste | 5,94 m | 4,32% |
Bedryfskoste | 14,38 m | 0,52% |
Netto inkomste | -10,72 m | 50,83% |
Netto winsgrens | -180,46 | 52,87% |
Wins per aandeel | — | — |
EBITDA | -9,51 m | 13,59% |
Effektiewe belastingkoers | 0,79% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
(USD) | Jun. 2024info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 63,89 m | -67,46% |
Totale bates | 233,31 m | -16,93% |
Totale aanspreeklikheid | 42,30 m | -30,22% |
Totale ekwiteit | 191,00 m | — |
Uitstaande aandele | 12,22 m | — |
Prys om te bespreek | 0,30 | — |
Opbrengs op bates | -11,12% | — |
Opbrengs op kapitaal | -13,33% | — |
Kontantvloei
Netto kontantverandering
(USD) | Jun. 2024info | J/J-verandering |
---|---|---|
Netto inkomste | -10,72 m | 50,83% |
Kontant van bedrywe | — | — |
Kontant van beleggings | — | — |
Kontant van finansiering | — | — |
Netto kontantverandering | — | — |
Beskikbare kontantvloei | — | — |
Meer oor
Prenetics is a health sciences company headquartered in Hong Kong with a significant presence in the United States. It is best known for its innovations in consumer and clinical health, focusing on early detection, prevention, and treatment of diseases, particularly cancer.
Prenetics' consumer initiatives are spearheaded by IM8, a health and wellness brand. Another key offering is CircleDNA, which utilizes next-generation sequencing technology to provide comprehensive DNA testing for consumers, offering insights into health, wellness, and genetic predispositions.
The company's clinical arm includes Insighta, a joint venture focused on developing multi-cancer early detection technologies. Additionally, ACT Genomics develops and provides a variety of genomic profiling panels, including ACTOnco, ACT HRD, ACTFusion, and ACTDrug tests, tailored to meet specific clinical needs. ACTLiquid Pro, a sequencing-based liquid biopsy assay, and ACTMonitor, which tracks drug resistance, treatment response, and cancer recurrence in real-time, are among its notable products. ACT Risk offers management solutions for assessing and mitigating cancer risks. Wikipedia
Gestig
2014
Webwerf
Werknemers
322